Skip to content
Screener

Alkermes ALKS Total Revenue

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$12.97B+5.7%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$1.07B+19.1%
AbbVie logo
AbbVieABBV
$16.99B+10.2%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$191.2M+57.4%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$317M+19.2%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$215.39M+16.6%

Segments

By product

See full
Vivitrol$124.45M
Aristada And Aristada Initio$96.72M
LUMRYZ$96.57M
LYBALVI$93.98M

By geography

See full
US$1.41B-5.5%
IE$1.29M+9.8%

Other financials

Income statement

See full
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
REVENUES:
Product sales, net$411,724$307,235$749,838$551,728
Manufacturing and royalty revenues84,28583,422139,082145,439
Total revenues496,009390,657888,920697,167
EXPENSES:
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)98,11249,460159,69098,657
Research and development112,92077,370216,265149,187
Selling, general and administrative217,625170,849482,218342,553

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's total revenue?
Alkermes (ALKS) reported total revenue of $496.01M in Q2 2026.
How has Alkermes's total revenue changed year-over-year?
Alkermes's total revenue increased by 27.0% year-over-year, from $390.66M to $496.01M.
What is the long-term trend for Alkermes's total revenue?
Over 4 years (2021 to 2025), Alkermes's total revenue has grown at a 5.9% compound annual growth rate (CAGR), from $1.17B to $1.48B.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Alkermes's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude